Data from the company’s first-in-human trial will be presented at the conference to be held on November 22-24, 2020, virtually, given the COVID-19 restrictions.
Superior performance and durability
Anteris chief executive officer Wayne Paterson said: “To be featured as a Best Innovation at PCR London Valves is a highly coveted honour, with all entries reviewed by a panel of independent experts.
“To be selected speaks to the quality of the clinical and pre-clinical evidence demonstrating the superior performance and durability of DurAVR™ and the genuine interest in its potential to significantly improve outcomes for patients.”
PCR London Valves is the world’s largest educational meeting focused on transcatheter therapies for valvular heart disease.
It attracts interventional cardiologists, cardiac surgeons, heart teams and industry partners committed to the field of structural heart solutions.
Presentations for 'Best Innovation' are selected in a competitive, peer-reviewed process with Anteris’ DurAVR™ the only aortic valve being featured in the Best Innovations section.
Professor Bart Meuris MD, PhD, chief of cardiovascular surgery at the University Hospitals, Leuven, Belgium and principal investigator of Anteris Technologies’ first-in-human study will present on the company’s behalf.
Dr Meuris will provide an overview of the DurAVR™ heart valve and results generated to date in the first-in-human study.
The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.